Screener
Fulgent Genetics, Inc. FLGT Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfNotesPayable.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flow from financing activities: | ||
| Repurchase of common stock | (40,078) | (8,679) |
| Common stock withholding for employee tax obligations | (4,200) | (1,887) |
| Repayment of notes payable | (476) | (470) |
| Principal paid for finance lease | (88) | (136) |
| Proceeds from exercise of stock options | 9 | — |
| Net cash used in financing activities | (44,833) | (11,172) |
| Effect of exchange rate changes on cash and cash equivalents | 3 | 11 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s debt repayments?
- Fulgent Genetics, Inc. (FLGT) reported debt repayments of $476K in Q1 2026.
- How has Fulgent Genetics, Inc.'s debt repayments changed year-over-year?
- Fulgent Genetics, Inc.'s debt repayments increased by 1.3% year-over-year, from $470K to $476K.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Fulgent Genetics, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude